Advertisement


Matteo Lambertini, MD, PhD, on Safety of Pregnancy After Treatment for BRCA-Mutated Breast Cancer

2019 ASCO Annual Meeting

Advertisement

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, discusses data from an international cohort study on counseling women with breast cancer who have a BRCA mutation about the safety of becoming pregnant once they complete treatment (Abstract 11506).



Related Videos

Lung Cancer

Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin

Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus cisplatin in terms of recurrence-free survival for patients with completely resected nonsquamous non–small cell lung cancer (Abstract 8501).

Lung Cancer

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer (Abstract 9008).

Hepatobiliary Cancer

Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil

Angela Lamarca, MD, PhD, of The Christie NHS Foundation Trust and the University of Manchester, discusses phase III findings from a multicenter study of active symptom control alone or active symptom control with oxaliplatin and fluorouracil for patients with locally advanced or metastatic biliary tract cancers previously treated with cisplatin and gemcitabine (Abstract 4003).

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Advanced Non–Small Cell Lung Cancer: KEYNOTE-001 Trial on Pembrolizumab

Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses long-term survival data on patients with advanced non–small cell lung cancer treated with pembrolizumab and those with PD-L1 expressed in at least half of their tumor cells (Abstract LBA9015).

Lung Cancer
Immunotherapy

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, of Hackensack University Medical Center, and Richard J. White, DO, of Allegheny Health Network, discuss improved overall survival among younger female patients with non–small cell lung cancer who have a lower comorbidity score, lower grade, private insurance, and treatment with intensity-modulated radiation therapy (Abstract 9024).

Advertisement

Advertisement




Advertisement